Orphan Nuclear Receptors in Drug Discovery
Identifieur interne : 000243 ( Pmc/Checkpoint ); précédent : 000242; suivant : 000244Orphan Nuclear Receptors in Drug Discovery
Auteurs : Yanhong ShiSource :
- Drug discovery today [ 1359-6446 ] ; 2007.
Abstract
Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and provide excellent drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in a number of important therapeutic areas, such as breast cancers, skin disorders, and diabetes. Orphan nuclear receptors, therefore, represent a tremendous opportunity in understanding and treating human diseases. This review highlights advances and potentials of using orphan nuclear receptors, in particular PPARs, Nurr1, RORs, and TLX as targets for drug discovery in diabetes and obesity, neurodegenerative diseases, and other related disorders.
Url:
DOI: 10.1016/j.drudis.2007.04.006
PubMed: 17532527
PubMed Central: 2748783
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:2748783Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Orphan Nuclear Receptors in Drug Discovery</title><author><name sortKey="Shi, Yanhong" sort="Shi, Yanhong" uniqKey="Shi Y" first="Yanhong" last="Shi">Yanhong Shi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17532527</idno><idno type="pmc">2748783</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748783</idno><idno type="RBID">PMC:2748783</idno><idno type="doi">10.1016/j.drudis.2007.04.006</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">000211</idno><idno type="wicri:Area/Pmc/Curation">000211</idno><idno type="wicri:Area/Pmc/Checkpoint">000243</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Orphan Nuclear Receptors in Drug Discovery</title><author><name sortKey="Shi, Yanhong" sort="Shi, Yanhong" uniqKey="Shi Y" first="Yanhong" last="Shi">Yanhong Shi</name></author></analytic><series><title level="j">Drug discovery today</title><idno type="ISSN">1359-6446</idno><idno type="e-ISSN">1878-5832</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p id="P1">Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and provide excellent drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in a number of important therapeutic areas, such as breast cancers, skin disorders, and diabetes. Orphan nuclear receptors, therefore, represent a tremendous opportunity in understanding and treating human diseases. This review highlights advances and potentials of using orphan nuclear receptors, in particular PPARs, Nurr1, RORs, and TLX as targets for drug discovery in diabetes and obesity, neurodegenerative diseases, and other related disorders.</p></div></front></TEI><pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9604391</journal-id><journal-id journal-id-type="pubmed-jr-id">21634</journal-id><journal-id journal-id-type="nlm-ta">Drug Discov Today</journal-id><journal-title>Drug discovery today</journal-title><issn pub-type="ppub">1359-6446</issn><issn pub-type="epub">1878-5832</issn></journal-meta><article-meta><article-id pub-id-type="pmid">17532527</article-id><article-id pub-id-type="pmc">2748783</article-id><article-id pub-id-type="doi">10.1016/j.drudis.2007.04.006</article-id><article-id pub-id-type="manuscript">NIHMS111265</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Orphan Nuclear Receptors in Drug Discovery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Yanhong</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><aff id="A1">Department of Neurosciences, Center for Gene Expression and Drug Discovery, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd, Duarte, CA 91010.</aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>To whom correspondence may be addressed. Tel: 626-301-8485; Fax: 626-471-7151; Email: <email>yshi@coh.org</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>28</day><month>4</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2007</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>9</month><year>2009</year></pub-date><volume>12</volume><issue>11-12</issue><fpage>440</fpage><lpage>445</lpage><abstract><title>Summary</title><p id="P1">Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and provide excellent drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in a number of important therapeutic areas, such as breast cancers, skin disorders, and diabetes. Orphan nuclear receptors, therefore, represent a tremendous opportunity in understanding and treating human diseases. This review highlights advances and potentials of using orphan nuclear receptors, in particular PPARs, Nurr1, RORs, and TLX as targets for drug discovery in diabetes and obesity, neurodegenerative diseases, and other related disorders.</p></abstract><kwd-group><kwd>Orphan Nuclear Receptor</kwd><kwd>ligand identification</kwd><kwd>peroxisome proliferator-activated receptors (PPARs)</kwd><kwd>TLX</kwd><kwd>Nur-related protein 1 (Nurr1)</kwd><kwd>retinoid acid receptor-related orphan receptors (RORs)</kwd><kwd>diabetes and obesity</kwd><kwd>neurodegenerative diseases</kwd></kwd-group><contract-num rid="NS1">R21 NS053350-01A1</contract-num><contract-num rid="NS1">R01 NS059546-01</contract-num><contract-sponsor id="NS1">National Institute of Neurological Disorders and Stroke : NINDS</contract-sponsor></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Shi, Yanhong" sort="Shi, Yanhong" uniqKey="Shi Y" first="Yanhong" last="Shi">Yanhong Shi</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000243 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000243 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:2748783
|texte= Orphan Nuclear Receptors in Drug Discovery
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:17532527" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |